Company intelligence / Profile preview

Shurl

Ownership: Private
Development stage: Other

Overview

ShuR is a biotechnology company focused on developing a novel class of therapeutics that target RNA-binding proteins (RBPs) to treat complex diseases. The company's proprietary platform leverages advanced computational biology and structural proteomics to identify and modulate specific RBP-RNA interactions that drive disease progression. By targeting these previously undruggable nodes in cellular regulation, ShuR aims to address high unmet needs in oncology and neurodegeneration. The company is currently advancing a pipeline of small molecule inhibitors designed to restore healthy RNA metabolism and cellular function.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Shurl.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shurl.

Explore the full profile